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Abstract
Background: Aberrant expression of miR-224 is associated with tumor development and progression. This study
investigated the role of miR-224 in esophageal squamous cell carcinoma (ESCC) ex vivo and in vitro.
Methods: A total of 103 esophageal intraepithelial neoplasia, ESCC tissue specimens, and their matched distant normal
tissues were collected to test miR-224 expression using qRT-PCR analysis. Western blot was used to quantify the level
of PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and PHLPP2 in ESCC tissues. Cell viability, apoptosis,
invasion, and colony formation assays were used to assess the altered phenotypes of esophageal cancer cell lines after
miR-224 expression or inhibition. A luciferase reporter assay was used to confirm miR-224 binding to PHLPP1 and
PHLPP2 mRNA.
Results: miR-224 was significantly overexpressed in esophageal intraepithelial neoplasia and ESCC tissues, while the
expression of PHLPP1 and PHLPP2 proteins, the target genes of miR-224, was downregulated in ESCC tissues. miR-224
expression was associated with advanced clinical TNM stage, pathologic grade, and the level of PHLPP1 and PHLPP2
proteins in ESCC tissues. Ectopic overexpression of miR-224 promoted proliferation, migration, and invasion, but
suppressed apoptosis of ESCC cells. miR-224 was able to bind to the 3′ untranslated region (3′-UTR) of PHLPP1 and
PHLPP2 mRNA to suppress their expression.
Conclusions: The current study demonstrated that miR-224 acts as an oncogenic miRNA in ESCC, possibly by
targeting PHLPP1 and PHLPP2.
Background
Esophageal cancer is a lethal disease with poor prog-
nosis. A large percentage of patients with esophageal
cancer are diagnosed at the advanced stages of disease
[1, 2]. Histologically, esophageal cancer occurs in two
major forms, esophageal squamous cell carcinoma
(ESCC) and esophageal adenocarcinoma, each of which
has distinct geographic patterns of incidence and risk
factors [3, 4]. Stretching from northern Iran through the
central Asian republics to North-Central China, ESCC is
the predominant histological subtype, accounting for
90 % of the total esophageal cancer cases [1]. To date,
surgery is the only cure option to treat esophageal can-
cer patients, but this only applies to limited numbers of
patients due to their inoperable disease; thus, the overall
five-year survival rate for the patients is 14 to 20 % [2].
Although multiple genetic and epigenetic alterations
have been detected in ESCC [5, 6], the precise patho-
genesis of ESCC remains to be discovered. Molecular
markers for early diagnosis and prediction of prognosis
or treatment responses are quite limited [4]. Thus,
further studies on the targeted prevention and early
detection of esophageal cancer could help to limit the
lethality of this disease.
microRNA (miRNA) is a class of small-regulatory
non-coding RNA molecules with 18 to 22 nucleotides
long. It can post-transcriptionally regulate gene expres-
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sion through pairing with the 3′-untranslated region
(UTR) of the targeted messenger RNAs (mRNA) and
control translation or induce degradation of target gene.
miRNA plays an important role in basic physiological
processes in cells, such as cell growth, differentiation,
apoptosis, energy metabolism, and immune response [7].
Previous studies demonstrated that aberrant miRNA ex-
pression can act as either a tumor suppressor or onco-
gene [8, 9]. A number of miRNA expression profiling
studies have been conducted in ESCC, and the ex-
pression of miRNAs, including miR-21, miR-25, and
miR-223 have been shown to be altered. These miRNAs
could be further evaluated as biomarkers for association
with ESCC progression and clinical outcome [9, 10].
Other studies showed that dysregulation of miR-145 and
miR-195 was able to modulate ESCC cell viability, pro-
liferation, invasion, and metastasis [8, 11]. In our unpub-
lished study, we identified several differentially expressed
miRNAs in ESCC tissues, compared to paired distant
normal tissues, using the Agilent microarray and found
several high expressed miRNAs, including miR-244. In-
deed, miR-224 has been reported to be dysregulated in
various human malignancies and can potentially affect
many cancer-related cellular processes, including gene
transcription, proliferation, differentiation, and cell death
[12, 13]. Bioinformatical studies have shown that miR-
224 may target PH domain leucine-rich repeat protein
phosphatase (PHLPP)-1 and PHLPP2, both of which
function as a tumor suppressor by blocking Akt signal-
ing. Down-regulation of PHLPP1 and PHLPP2 proteins
has been found in a variety of malignant tumors, in-
cluding colorectal cancer [14], prostate cancer [15], and
chronic lymphocytic leukemia (CLL) [16].
In this study, we first assessed miR-244 expression in
esophageal intraepithelial neoplasia biopsies, ESCC tis-
sues, and their matched distant normal tissues, then as-
sociated the expression pattern with clinicopathological
features from ESCC patients. We also examined the ef-
fects of miR-224 expression or inhibition on regulation
of ESCC cell viability and mobility and investigated the




In this study, we collected 103 cases of esophageal patients
from General Surgery Department and Digestive Disease
Department, The First Affiliated Hospital of Nanjing Med-
ical University (Jiangsu, China), between January 2013 and
December 2013. Patients who had received radiotherapy,
chemotherapy, or other esophageal surgery before esopha-
gectomy were excluded. Specifically, we obtained 10 pairs
of low-grade intra-epithelial neoplasia (LG-IEN) biopsies
and their matched distant normal tissues (5 cm away from
the lesion), 30 pairs of HG-IEN biopsies and their matched
distant normal tissues, and 63 pairs of ESCC tissues and
their matched normal esophageal tissues (5 cm away from
tumor lesion according to NCCN guideline of esophageal
cancer) for this study. Patients with a postoperative patho-
logical result including both IEN and ESCC were included
into ESCC group. And only those paitients who had IEN
only were included in the IEN group. All tissue specimens
were immediately snap-frozen in liquid nitrogen and then
stored at −80 °C. This study was approved by the Ethics
Committee of the First Affiliated Hospital of Nanjing Med-
ical University, and a written informed consent was ob-
tained from each patient.
RNA isolation and quantitative reverse-transcriptase-
polymerase chain reaction (qRT-PCR)
Total cellular RNA was isolated from tissue specimens or
cell lines using the Trizol reagent (TaKaRa, Dalian, China),
according to the manufacturer’s instructions. For qRT-PCR,
2 μg each of these RNA samples were reversely transcribed
into cDNA using PrimeScript RT Master Mix (TaKaRa),
and PCR amplification was performed at an initial 95 °C for
5 min and then 40 cycles of 95 °C for 20 s, 60 °C for 20 s,
and 70 °C for 10 s in the StepOnePlus™ PCR system (ABI,
USA) using SYBR Premix Ex Taq (Takara), according to the
manufacturer’s procedures. The qRT-PCR miRNA Primer
Set (one RT primer and a pair of qPCR primers for each
set) specific for miR-224 was designed and synthesized by
RiboBio (Guangzhou, China). U6 small nuclear RNA was
used to normalize miR-224 expression. All qRT-PCR amp-
lification was performed in triplicate and repeated at least
once. The relative miR-224 expression levels after
normalization to U6 small nuclear RNA were calculated
using 2-[(Ct of miR-224) – (Ct of U6)]. The increasing fold of
miR-224 were expressed relative to the matched normal tis-
sues and calculated using 2-ΔΔCT(ΔΔCT=ΔCTIEN/ESCC-
ΔCTNormal). All data after logarithm transition (y =
LnX) were applied for the statistical analysis.
Cell lines and culture
Human ESCC cell line TE13 and Eca109 were obtained
from Shanghai Institute of Biochemistry and Cell Biology
(Shanghai, China) and cultured in Rosewell Park Memorial
Institute (RPMI)-1640 medium with 10 % fetal bovine
serum (FBS; Invitrogen, Carlsbad, CA, USA) in a humidi-
fied incubator with 5.0 % CO2 at 37 °C. To avoid possible
effects on gene expression, antibiotic was not used in cell
culture.
Transient gene transfection into ESCC cell lines
hsa-miR-224 mimic, miR-224 negative control (NC),
miRNA-224 inhibitor, and miRNA-224 inhibitor negative
control (INC) were purchased from Genepharma (Shanghai,
China). hsa-miR-224 mimic and NC were incomplete
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complementary double stranded, while miRNA-224 in-
hibitor and INC were single stranded. All oligonucleotide
sequences are listed in Table 1. ESCC cells were seeded
and grown overnight and next day, these RNA oligonucle-
otides were transiently transfected into cells using Lipofec-
tamine 2000 (Invitrogen), according to the manufacturer’s
protocol. After 24 or 48 h incubation, the cells were har-
vested and subjected to different experiments.
Cell viability assay
After transfection with aforementioned RNA oligonucleo-
tides, TE13 and Eca109 cells were seeded in 96-well plates
at a density of 4000 cells/well and cultured for 24 to 96 h.
At the end of each experiment, Cell Counting Kit-8
(Dojindo, Shanghai, China) reagents were added into each
well and the plates were incubated for 1.5 h, and the optical
density (OD) was then measured at 450 nm using Nano-
Drop 2000 (Thermo, USA). The experiments were per-
formed in 5 replicates and repeated three times.
Colony formation assay
Forty-eight h after transfection with RNA oligonucleotides,
cells were trypsinized and plated on 6-well plates at a dens-
ity of 300 cells/well and cultured for 10 days. The colonies
were then fixed with methanol for 15 min and stained with
0.4 % crystal violet at the room temperature for 30 min.
The number of colonies, which were defined as > 50 cells/
colony, were counted. The experiments were performed in
triplicate and repeated three times.
Flow cytometric apoptosis assay
Forty-eight hours after transfection with RNA oligonucleo-
tides, cells were harvested through trypsinization and
washed two times with phosphate buffered saline (PBS).
Apoptosis was assessed using a FITC Annexin V Apoptosis
Kit (Becton Dickinson, Franklin Lakes, NJ, USA), according
to the manufacturer’s instructions. Cells were then analyzed
using a flow cytometer (Becton Dickinson) within 1 h of
staining using the FL1-H (FITC) and FL2-H (PI) lines.
Tumor cell migration and invasion assay
Tumor cell migration and invasion were assayed using
24-well Transwell plates with 8 mm pore size (Millipore,
Bedford, MA, USA). For migration assay, 48 h after
transfection with RNA oligonucleotides, ESCC cells were
trypsinized, washed, resuspended in 2 % FBS-containing
medium, and added to the upper chamber, while 15 %
FBS-containing medium was added to the bottom cham-
bers. The Transwell chambers were incubated at 37 °C
for 48 h and non-migrating cells were removed by a cot-
ton swab, while the migrated cells were fixed, stained
with crystal violet, and counted for ten random fields/
chamber. The experiments were conducted in triplicate
and repeated three times. Tumor cell invasion assay was
the same as the migration assay, except that the mem-
branes were coated with Matrigel (BD) and the Trans-
well plates were fixed and stained 72 h after the invasion
assay.
Luciferase assay
Using online tools, including miRBase, TargetScan, and
miRDB, we found that PHLPP1 and PHLPP2 are poten-
tially targeted by miR-224. The miR-224 binding site is
localized between 518 to 524 bp of the PHLPP1 3′-UTR
(a total of 1002 bp long) or between 3562 to 3568 bp of














were generated by Invitrogen-China. Eca109 and TE13 cells
were then co-transfected with pGL3-3′-UTR and miR-224
mimic or inhibitor, or their matched miR-negative control.
After 24 h transfection, Firefly and Renilla luciferase activity
was measured using the Dual Luciferase Assay kit (Pro-
mega, Madison, WI, USA), according to the manufacturer’s
instructions. The data were normalized against the activity
of the Renilla luciferase. The experiments were performed
in triplicate and repeated three times.
Protein extraction and Western blot
Tissue specimens and cells were homogenized, and the
total cellular protein was extracted using the RIPA Lysis
Buffer (Beyotime, Jiangsu, China), according to the man-
ufacturer’s instructions. Protein concentration was mea-
sured by the BCA method (Beyotime). Western blot was
performed using anti-phospho-AKT, anti-AKT, anti-
GAPDH (Cell Signaling Technology, Danvers, MA, USA),
Table 1 Oligonucleotide sequences
Name Oligonucleotide sequences




miR-224 inhibitors single strand 5′-AACGGAACCACUAGUGACUUG-3′
INC single strand 5′-CAGUACUUUUGUGUAGUACAA-3′
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anti-PHLPP1, and anti-PHLPP2 (Abcam, Cambridge, MA,
USA) antibodies. The relative levels of protein expression
were quantified by densitometric scanning (Image J Soft-
ware, NIH, Bethesda, MD, USA), and the relative gray
values of protein levels were calculated based on the band
intensity of protein of interest divided by the band intensity
of loading control.
Immunofluorescence
Seventy-two h after gene transfection, Eca109 cells were
fixed in 4 % paraformaldehyde for 15 min at the room
temperature, washed three times in PBS, and incubated
for 60 min at the room temperature in a blocking solution
(Beyotime). The primary antibody (anti-PHLPP1 and
anti-PHLPP2 from Abcam) in the blocking reagent
was added and incubated overnight at 4 °C. The next
day, the cells were washed with PBS for three times,
and the fluorescent probe conjugated secondary anti-
body (Jackson ImmunoResearch, USA) was added to the
cells. The cells were further incubated for 60 min at the
room temperature and then washed three times in PBS. Cell
nucleus was counterstained with DAPI (Beyotime). Photos
were then taken using a Nikon Fluorescence microscope.
Statistical analysis
The data were summarized as mean ± S.D. and analyzed
using Student’ t-test, Chi-square test, mono factor analysis
of variance, and the correlation analysis with SPSS 17.0
Fig. 1 Overexpression of miR-224 in esophageal intraepithelial neoplasia and ESCC tissues. a qRT-PCR. miR-224 expression was assessed in 40 pairs
of IEN (intraepithelial neoplasia) biopsies and their matched adjacent normal tissues and 63 pairs of ESCC tissues and their matched normal esophageal
tissues. Each point represents the mean of three independent experiments. The horizontal lines represent the median in each group. b Comparison of
miR-224 expression in tissues obtained from ESCC and IEN patients. The horizontal lines represent the mean in each group. c Comparison of mean
miR-224 expression stratified by TNM and pathologic classification. The horizontal lines represent the mean in each group. d qRT-PCR. Expression of
miR-224 in esophageal cancer Eca109 and TE13 cell lines after transfected with miR-224 mimics or inhibitors. *p < 0.05 and **p < 0.01
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software (SPSS, Chicago, IL, USA). A p-value less than
0.05 was considered to be statistically significant.
Results
Overexpression of miR-224 is in esophageal intraepithelial
neoplasia and ESCC tissue specimens
miR-224 was significantly overexpressed in esophageal
intraepithelial neoplasia and ESCC tissue samples com-
pared to that of the matched distant normal tissues
(p < 0.05, Fig. 1a; Additional file 1: Figure S1 and
Additional file 2: Figure S2). Specifically, qRT-PCR
data showed that expression of miR-224 was increased for
more than two folds in 70 % of ESCC patients compared
to normal mucosae (Additional file 1: Figure S1). More-
over, miR-224 expression was significantly different be-
tween ESCC and IEN (p < 0.001, Fig. 1b). To further
investigate clinicopathological significance of miR-224
expression in ESCC patients, we chose the mean of fold
increase of miR-224 expression in ESCC samples as the
cut-off point of low and high expression of miR-224. We
found that miR-224 expression was associated with ESCC
pathologic grade (p < 0.01, Fig. 1c and Table 2) and TNM
stage (p < 0.01, Fig. 1c and Table 2), but not with other
clinicopathological data from the patients (Table 2).
Ectopic expression of miR-224 changed phenotypes of
ESCC cell in vitro
Next, we altered miR-224 expression in esophageal
cancer cell lines. As shown in Fig. 1d, transfection with
miR-224 mimics or inhibitor significantly up- or down-
regulated the level of miR-224 expression in Eca109 and
TE13 cells compared to the control oligonucleotides-
transfected cells.
We then assessed the phenotypes of Eca109 and
TE13 cell lines. The CCK-8 assay revealed that overex-
pression of miR-224 significantly increased viability of
Eca109 and TE13 cell lines compared to negative con-
trol (NC)-transfected cells, whereas transfection of
anti-miR-224 reduced tumor cell viability (p < 0.05,
Fig. 2a). Moreover, tumor cell colony formation assay
showed that miR-224 mimic increased the colony-
forming efficiency of Eca109 cells, whereas anti-miR-
224 suppressed the colony-forming efficiency of Eca109
cells (p < 0.05, Fig. 2b). In addition, the flow cytometry
assay showed that anti-miR-224 increased apoptosis of
both ESCC cell lines compared to the negative control
(p < 0.05, Fig. 2c).
Furthermore, as shown in Fig. 3, overexpression of
miR-224 significantly promoted migration and invasion
of Eca109 and TE13 cell lines, whereas anti-miR-224
suppressed migration and invasion of these two cell lines
compared to the negative control.
miR-224 directly targets tumor suppressor gene PHLPP1
and PHLPP2 in ESCC cells
To predict miR-224 targets, we utilized Bioinformatical
algorithms of miRBase, TargetScan, and miRDB and
showed that miR-224 could bind to the 518–524 bp and
3562–3568 bp, 3′-UTR region of PHLPP1 and PHLPP2,
respectively (Fig. 4a). To confirm this prediction, we con-
structed luciferase reporter vectors and performed the
luciferase reporter assay. The data showed that miR-224
mimic significantly reduced both PHLPP1 and PHLPP2
reporter gene luciferase activity compared to the controls.
In contrast, miR-224 inhibitor significantly promoted
both PHLPP1 and PHLPP2 reporter gene luciferase
activity (p < 0.05, Fig. 4b). Mutations of the potential miR-
224-binding sites of PHLPP1 and PHLPP2 3′-UTRs pre-
vented the ability of miR-224 mimics and inhibitor to alter
luciferase activity, suggesting that miR-224 is able to target
the predicted PHLPP1 and PHLPP2 binding site. Indeed,
qRT-PCR, immunofluorescence, and Western blotting
data showed no change in the levels of PHLPP1 or
PHLPP2 mRNA in miR-224-transfected cells compared to
Table 2 Association of miR-224 expression with clinicopathological
features from ESCC patients
Characteristics miR-224 expression P valuea
High Low
Age (years)
≥60 22 15 0.658
<60 14 12
Gender
Male 28 17 0.198
Female 8 10
Tumor localizationb
Upper third 3 5 0.442
Middle third 17 10
Lower third 16 12
Tumor length (cm)












bClassified according to the AJCC, 7th edition, staging criteria for
esophageal cancer
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Fig. 2 (See legend on next page.)
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the controls (p > 0.05, Fig. 4c), whereas levels of their
proteins were dramatically down-regulated in miR-
224-overexpressing cells and up-regulated after inhibi-
tion of miR-224 expression in esophageal cancer cell
lines (p < 0.05, Fig. 5). These data indicated that miR-224
affects translation of PHLPP mRNA.
Ectopic expression of miR-224 affected the Akt signaling
in ESCC cells
To explore the possible underlying molecular mecha-
nisms of miR-224 action in ESCC cell lines, we analyzed
the downstream signals of PHLPP1 and PHLPP2. As
shown in Fig. 5a, phosphorylation levels of AKT protein
was increased in miR-224-overexpressing ESCC cells,
whereas anti-miR-224 suppressed the levels of phosphory-
lated AKT protein compared to the negative control.
Down-regulated PHLPP1 and PHLPP2 expression
associated with miR-224 expression in ESCC tissues
The level of PHLPP1 and PHLPP2 protein was sig-
nificantly reduced in 12 cases of ESCC tissue samples
compared to that of the matched distant normal tissues
(See figure on previous page.)
Fig. 2 Ectopic miR-224 expression changed the phenotypes of ESCC cell in vitro. a Cell viability CCK-8 assay. The effects of miR-224 on ESCC cell
proliferation ability. b Colony formation assay. The effects of miR-224 on Eca109 cell line colony formation ability. c Flow cytometric apoptosis
assay. miR-224I increased apoptosis of ESCC cell lines compared to the negative control. Apoptotic cells (%) = Q2 + Q3. Error bars represent the
mean ± SD of three independent experiments. OD, optical density; miR-224 M, miR-224 mimic; miR-224I, miR-224 inhibitor; NC, negative control;
*p < 0.05 and **p < 0.01
Fig. 3 Ectopic miR-224 expression altered the ability of ESCC cell migration and invasion. Esophageal cancer Eca109 and TE13 cell lines were
grown and transiently transfected with miR-224 mimics or inhibitor, and then subjected to migration and invasion assays. The data showed that
overexpression of miR-224 significantly promoted migration and invasion of Eca109 and TE13 cells, whereas anti-miR-224 significantly suppressed
migration and invasion. Error bars represent the mean ± SD of three independent experiments. miR-224 M, miR-224 mimic; miR-224I, miR-224
inhibitor; NC, negative control; *p < 0.05 and **p < 0.01
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(p < 0.05, Fig. 6a and Additional file 3: Figure S3).
Correlation analysis showed that expression of PHLPP1
and PHLPP2 proteins was associated with miR-224
expression in ESCC tissues (the correlation coefficient
was −0.596 and −0.620, respectively; p < 0.05, Fig. 6b).
Discussion
In the current study, we first assessed miR-244 expression
in esophageal IEN biopsies, ESCC tissues, and their
matched distant normal tissues, and associated the expres-
sion pattern with clinicopathological features from ESCC
patients. We also investigated the effects of miR-224 ex-
pression or inhibition on regulation of ESCC cell viability
and invasion capacity, and determined the underlying mo-
lecular mechanisms in esophageal cancer cells in vitro.
We found that miR-224 was up-regulated in esophageal
IEN and ESCC tissue specimens compared to that of the
matched distant normal tissues, and miR-224 expression
was associated with aggressive characteristics of IEN and
ESCC. Furthermore, ectopic overexpression of miR-224
promoted proliferation, migration, and invasion, but sup-
pressed apoptosis of ESCC cells in vitro. miR-224 was able
to bind to PHLPP1 and PHLPP2 3′-UTR and suppressed
their expression and may subsequently induced activity of
the AKT signaling, while the levels of PHLPP1 and
PHLPP2 proteins were associated with miR-224 expression
in ESCC tissues. Our current data indicates that miR-224
is an oncogenic miRNA and targets expression of PHLPP1
and PHLPP2 proteins in ESCC.
Nevertheless, it should be noted that miR-224 can be
up-regulated or down-regulated in different types or
subtypes of cancer. For example, miR-224 expression
was frequently up-regulated in hepatocellular carcinoma
[17], colorectal cancer [18], medulloblastoma [19],
Fig. 4 PHLPP1 and PHLPP2 as target genes of miR-224 in ESCC cells. a Predicted miR-224 target sequences in PHLPP1 and PHLPP2 3′-UTRs. The
mutated nucleotides in PHLPP1 and PHLPP2 3′-UTRs used for our experiments are highlighted in red. b Luciferase assay. Interaction of miR-224
with 3′-UTR of PHLPP1 and PHLPP2 was confirmed by the luciferase assay in Eca109 and TE13 cells. c qRT-PCR. The data showed that miR-224 did
not affect expression of PHLPP1 and PHLPP2 mRNA in Eca109 and TE13 cells (p > 0.05). Error bars represent the mean ± SD of three independent
experiments. miR-224 M, miR-224 mimic; miR-224I, miR-224 inhibitor; NC, negative control; *p < 0.05 and **p < 0.01
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thyroid cancer [20], pancreatic ductal adenocarcinoma
[21], renal cancer [22], cervical cancer [23], and glioma
[24]. In contrast, down-regulation of miR-224 has been ob-
served in prostate cancer [25], ovarian cancer [26], giant
cell tumor [27], and oral cancer [28]. These data suggest
that miR-224 can function as an oncogene or tumor sup-
pressor through regulating the expression of different target
genes. For example, in hepatocellular carcinoma, ectopic
overexpression of miR-224 significantly down-regulated
HOXD10 expression and promoted cell migration and in-
vasion [12], whereas inhibition of miR-224 expression en-
hanced cell migration and invasion of prostate cancer cells
through direct regulation of oncogenic TPD52 [29]. In
support of the tumor-promoting role of miR-224 in ESCC,
Fig. 5 Ectopic miR-224 expression affected expression of PHLPP1 and PHLPP2 proteins and changed the AKT signaling in ESCC cells. a Western
blot. Esophageal cancer Eca109 and TE13 cell lines were grown and transiently transfected with miR-224 mimics and inhibitor, and then subjected
to Western blot analysis. b Immunofluorescence analysis of PHLPP1 and PHLPP2 expression in transfected Eca109 cell line. From the left to right,
the first panel is DAPI staining, the second is PHLPP1/2 staining, and the third one is overlap. Error bars represent the mean ± SD of three independent
experiments. miR-224 M, miR-224 mimic; miR-224I, miR-224 inhibitor; NC, negative control; *p < 0.05 and **p < 0.01
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our current data showed that miR-224 was up-regulated
in esophageal IEN and ESCC tissue specimens compared
to that of the matched distant normal tissues, and miR-
224 expression was associated with aggressive characteris-
tics of IEN and ESCC. These data further confirmed
that miR-224 can function as an oncogene by regulat-
ing the expression of PHLPP1 and PHLPP2 proteins.
Furthermore, our current data also showed that ec-
topic overexpression of miR-224 promoted prolifera-
tion, migration, and invasion, but suppressed apoptosis
of ESCC cells in vitro, which is consistent with the data
on HCC [12]. Importantly, our current study further
confirmed that PHLPP1 and PHLPP2 are two target
genes of miR-224. Both of PHLPP1 and PHLPP2 pro-
teins contain each of a PH domain, leucine-rich repeat,
phosphatase domain, and PDZ-binding motif [30]. As
tumor-suppressor phosphatases, PHLPP1 and PHLPP2
proteins act to suppress cell survival pathways. They
can directly dephosphorylate a conserved regulatory
site (termed the hydrophobic motif ) of Akt protein,
protein kinase C, and S6 kinase. In turn, these
phosphatases block signaling of these pro-survival
kinases, and promote apoptosis and suppress tumor
growth [30, 31]. A number of studies showed altered
expression of PHLPP1 and PHLPP2 and their functions
in various malignancies [32, 33]. Indeed, a previous
study showed expression and association between miR-
224 and PHLPPs in colorectal cancer [13]. Another
study reported by Cai et al. [34] suggested that PHLPP2
was a bona fide target gene of miR-205 and associated
the up-regulation of miR-205 with cell growth and
vascularization. Our current data further demonstrated
that the loss of PHLPP1 and PHLPP2 expression oc-
curred in ESCC tissue samples and their expression
was associated with miR-224 expression in ESCC tis-
sues. These data revealed the mechanisms responsible
for PHLPP expression, because to date, little is known
regarding regulation of PHLPP expression in different
human cells [35].
However, our current study is limited to proof-of-
principle and further investigations are needed to under-
stand the role of miR-224 in esophageal cancer and
Fig. 6 Down-regulated of PHLPP1 and PHLPP2 expression associated with miR-224 in ESCC. a ESCC and their matched normal esophageal tissue
specimens from 12 patients were subjected to Western blot analysis. The relative gray values of protein were calculated as band intensity of protein of
PHLPPs/band intensity of GAPDH. Error bars represent the mean ± SD of three independent experiments. b Correlation analysis of miR-224 expression
and PHLPPs protein levels in ESCC tissues. *p < 0.05 and **p < 0.01c
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clarify how miR-224 regulates expression of PHLPP1
and PHLPP2 proteins during esophageal cancer com-
pared to other cancer pathogenesis.
Conclusions
In summary, our current study showed that miR-224 up-
regulation could promote ESCC development, possibly
through inhibiting PHLPP1 and PHLPP2 expression, indi-
cating that miR-224 has oncogenic activity in ESCC. These
findings may not only increase our understanding of ESCC
development and progression, but may also help us to de-
velop a novel therapeutic strategy for ESCC.
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